{"id":56275,"date":"2026-08-21T08:42:05","date_gmt":"2026-08-21T08:42:05","guid":{"rendered":"https:\/\/www.vtmarkets.com\/sv-eu\/uncategorized\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/"},"modified":"2026-08-21T08:42:05","modified_gmt":"2026-08-21T08:42:05","slug":"moderna-merck-and-the-different-ways-markets-value-a-breakthrough","status":"publish","type":"post","link":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","title":{"rendered":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott"},"content":{"rendered":"<figure class=\"wp-block-post-featured-image\"><img loading=\"lazy\" decoding=\"async\" width=\"1250\" height=\"700\" src=\"https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma.webp\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" style=\"object-fit:cover;\" srcset=\"https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma.webp 1250w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-300x168.webp 300w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-1024x573.webp 1024w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-768x430.webp 768w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-500x280.webp 500w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-400x224.webp 400w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-350x196.webp 350w, https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma-200x112.webp 200w\" sizes=\"auto, (max-width: 1250px) 100vw, 1250px\" \/><\/figure>\n\n\n<p class=\"wp-block-paragraph\">Onsdagen den 19 augusti meddelade Moderna att bolagets personanpassade mRNA\u2011baserade cancerbehandling (mRNA \u00e4r ett slags genetiskt \u201dinstruktionsmeddelande\u201d som f\u00e5r kroppen att tillverka ett visst protein) hade <a href=\"https:\/\/www.cnbc.com\/2026\/08\/19\/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html\">lyckats i en fas 3\u2011studie<\/a> (sen klinisk huvudstudie p\u00e5 m\u00e5nga patienter). Aktien rusade. Kursen steg 177%, <a href=\"https:\/\/www.wsj.com\/health\/pharma\/moderna-merck-vaccine-succeeds-in-preventing-melanoma-from-returning-540e9e18?mod=hp_lead_pos5\">mer \u00e4n en f\u00f6rdubbling under en enda handelsdag<\/a>, och st\u00e4ngde \u00f6ver 174 dollar. Merck, som samarbetar med Moderna i programmet, steg ocks\u00e5 \u2013 upp 12,6%.<\/p>\n\n\n\n<script type=\"module\" src=\"https:\/\/widgets.tradingview-widget.com\/w\/en\/tv-tickers.js\"><\/script>\n\n<tv-tickers symbols=\"NASDAQ:MRNA,NYSE:MRK\" hover-type=\"performance-grid\" show-hover><\/tv-tickers>\n\n\n\n<p class=\"wp-block-paragraph\">Reaktionen blev inte lika varaktig. P\u00e5 torsdagen f\u00f6ll Moderna som mest 25% till omkring 129 dollar och st\u00e4ngde till slut runt -19%. N\u00e4stan <a href=\"https:\/\/www.forbes.com\/sites\/tylerroush\/2026\/08\/20\/moderna-stock-plunges-25-wiping-out-18-billion-after-historic-cancer-vaccine-breakthrough\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">18 miljarder dollar i b\u00f6rsv\u00e4rde raderades<\/a>. Merck st\u00e4ngde samtidigt ned bara 0,57%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Studieresultatet hade inte \u00e4ndrats. Det som drev upp Moderna dagen f\u00f6re g\u00e4llde \u00e4ven p\u00e5 torsdagen. Skillnaden l\u00e5g i hur investerare bed\u00f6mde bolagens f\u00f6rm\u00e5ga att g\u00f6ra forskning till int\u00e4kter p\u00e5 sikt \u2013 gapet mellan fynd och aff\u00e4rsv\u00e4rde.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Vad studien visade<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Intismeran autogene \u00e4r en personanpassad cancerbehandling som tas fram utifr\u00e5n de mutationer (genf\u00f6r\u00e4ndringar) som finns i varje enskild patients tum\u00f6r. M\u00e5let \u00e4r att l\u00e4ra immunf\u00f6rsvaret att k\u00e4nna igen och angripa dessa m\u00e5l i cancern.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Behandlingen ges tillsammans med <a href=\"https:\/\/www.merck.com\/news\/keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-plus-paclitaxel-%C2%B1-bevacizumab-approved-for-certain-adults-with-pd-l1-cps-%E2%89%A51\/\">Mercks Keytruda<\/a> (immunterapi som hj\u00e4lper immunf\u00f6rsvaret att angripa cancer), inte som ers\u00e4ttning.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I <a href=\"https:\/\/www.merck.com\/news\/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient\/\">INTerpath\u2011001\u2011studien<\/a> n\u00e5dde kombinationen sitt prim\u00e4ra m\u00e5l (det viktigaste m\u00e5ttet i studien) om \u00e5terfallsfri \u00f6verlevnad, samt ett sekund\u00e4rt m\u00e5l (extra m\u00e5tt) om \u00f6verlevnad utan fj\u00e4rrmetastaser (spridning till andra organ), hos patienter med melanom (hudcancer) i stadium IIB till IV efter operation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det var den f\u00f6rsta positiva fas 3\u2011studien f\u00f6r en mRNA\u2011baserad cancerbehandling.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Men en detalj stack ut. Pressmeddelandet inneh\u00f6ll inte hazardkvoter (m\u00e5tt p\u00e5 skillnad i risk \u00f6ver tid mellan tv\u00e5 grupper) eller mer detaljerade effektdata. B\u00f6rsen r\u00f6rde sig kraftigt p\u00e5 en kort \u201dtopline\u201d\u2011signal om framg\u00e5ng innan helheten visats. D\u00e5 prissatte investerare inte bara forskningen, utan ocks\u00e5 m\u00f6jlig f\u00f6rs\u00e4ljning.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Samma genombrott, olika b\u00f6rsv\u00e4rde<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Moderna har tagit fram behandlingen och \u00e4ger mRNA\u2011plattformen (teknik och processer f\u00f6r att utveckla mRNA\u2011l\u00e4kemedel). Merck bidrog med Keytruda, vana av myndighetsprocesser (godk\u00e4nnanden) och global f\u00f6rs\u00e4ljningskraft.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">B\u00e5da gynnas av resultatet, men investerare ser m\u00f6jligheterna olika.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>F\u00f6r Moderna \u00f6ppnar studien fler v\u00e4gar. En fungerande personanpassad \u201dcancervaccin\u201d\u2011plattform (vaccin h\u00e4r betyder behandling som tr\u00e4nar immunf\u00f6rsvaret) kan p\u00e5 sikt anv\u00e4ndas mot flera cancertyper.<\/li>\n\n\n\n<li>F\u00f6r Merck \u00e4r nyttan mer direkt. Behandlingen kan st\u00e4rka Keytruda\u2011aff\u00e4ren<a href=\"https:\/\/www.businesstimes.com.sg\/international\/merck-create-separate-cancer-business-keytruda-patent-loss-looms\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\"> n\u00e4r bolaget n\u00e4rmar sig ett av branschens st\u00f6rsta patentutg\u00e5ngar<\/a> (n\u00e4r patentet l\u00f6per ut \u00f6kar konkurrensen fr\u00e5n kopior).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Marknaden fr\u00e5gade inte bara: \u201dVem gjorde genombrottet?\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Utan: \u201dVem kan b\u00e4st tj\u00e4na pengar p\u00e5 det?\u201d<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Mercks tydligare v\u00e4g till int\u00e4kter<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Mercks utmaning \u00e4r tydlig: ers\u00e4tta int\u00e4kter fr\u00e5n Keytruda innan patentskyddet upph\u00f6r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Keytruda <a href=\"https:\/\/finance.yahoo.com\/news\/keytruda-aid-mrks-growth-2026-144800572.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">drog in cirka 25,3 miljarder dollar i \u00e5rsoms\u00e4ttning<\/a> och <a href=\"https:\/\/www.barrons.com\/articles\/keytruda-gardasil-sales-merck-stock-c19d0661\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">\u00e4r ett av v\u00e4rldens st\u00f6rsta l\u00e4kemedel<\/a>. Exklusiviteten i USA l\u00f6per ut i december 2028. Samtidigt b\u00f6rjar pris\u00e5tg\u00e4rder inom Inflation Reduction Act (amerikansk lag som kan pressa l\u00e4kemedelspriser via offentliga program) p\u00e5verka utvalda l\u00e4kemedel fr\u00e5n januari 2028.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det ger Merck en tydlig tidsplan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En framg\u00e5ngsrik kombinationsbehandling med intismeran kan f\u00f6rl\u00e4nga Keytrudas kommersiella liv. I st\u00e4llet f\u00f6r att l\u00e4gga till en helt frist\u00e5ende produkt kan Merck f\u00f6rst\u00e4rka en befintlig behandling med en ny generation cancerterapi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det var en m\u00f6jlighet som investerarna tog fasta p\u00e5.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Morgan Stanley <a href=\"https:\/\/finance.yahoo.com\/markets\/stocks\/articles\/morgan-stanley-revamps-merck-stock-201857782.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">h\u00f6jde Merck till \u201dOverweight\u201d<\/a> (rekommendation om att \u00e4ga mer \u00e4n index), och m\u00e5nga <a href=\"https:\/\/www.gurufocus.com\/news\/9045774\/morgan-stanley-revamps-merck-stock-target-after-cancer-breakthrough?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">analytiker h\u00f6jde riktkurserna<\/a>, med argumentet att projektportf\u00f6ljen (pipeline: kommande l\u00e4kemedel under utveckling) inklusive intismeran kan d\u00e4mpa effekten av Keytruda\u2011patentets utg\u00e5ng.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Merck gick in i beskedet med starkare finanser. Enbart Keytruda gav \u00f6ver 16 miljarder dollar i kassafl\u00f6de (pengar in minus pengar ut i verksamheten) under f\u00f6rsta halv\u00e5ret 2026, vilket ger st\u00f6rre utrymme att investera, utveckla och lansera nya behandlingar.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Moderna m\u00e5ste g\u00f6ra potential till int\u00e4kter<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">F\u00f6r Moderna ser bilden annorlunda ut.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bolaget har en v\u00e4rdefull teknikplattform, men m\u00e5ste fortfarande visa att den ger stabila vinster \u00f6ver tid.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I <a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/moderna-q2-earnings-call-highlights-140404872.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">andra kvartalet 2026<\/a> redovisade Moderna 145 miljoner dollar i int\u00e4kter och en nettof\u00f6rlust p\u00e5 782 miljoner dollar. Kostnaderna f\u00f6r forskning och utveckling (FoU) var 651 miljoner dollar, mer \u00e4n fyra g\u00e5nger int\u00e4kterna.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vid utg\u00e5ngen av juni hade bolaget 6,9 miljarder dollar i kassa och placeringar, ned fr\u00e5n 7,5 miljarder tre m\u00e5nader tidigare. Ledningen r\u00e4knar med 4,7\u20135,2 miljarder dollar vid \u00e5rets slut.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Samtidigt har inte alla mRNA\u2011projekt g\u00e5tt som planerat. Modernas <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-07-31\/moderna-says-early-results-of-norovirus-shot-were-not-successful\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">noroviruskandidat mRNA\u20111403 n\u00e5dde inte kraven f\u00f6r statistisk s\u00e4kerhet<\/a> (tillr\u00e4ckligt tydligt resultat enligt f\u00f6rutbest\u00e4mda regler) i en interimsanalys (f\u00f6rhandsgranskning) i fas 3.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cancerresultatet \u00e4ndrade framtidsutsikterna, men f\u00f6r\u00e4ndrade inte omedelbart ekonomin.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td class=\"has-text-align-center\" data-align=\"center\"><\/td><td class=\"has-text-align-center\" data-align=\"center\">Moderna<\/td><td class=\"has-text-align-center\" data-align=\"center\">Merck<\/td><\/tr><tr><td>Huvudbidrag<\/td><td>mRNA-plattform och personanpassad behandling<\/td><td>Keytruda, f\u00f6rs\u00e4ljningskraft och distribution<\/td><\/tr><tr><td>L\u00e4ge Q2 2026<\/td><td>145 MUSD i int\u00e4kter, 782 MUSD i nettof\u00f6rlust<\/td><td>Keytruda gav \u00f6ver 16 MdUSD i kassafl\u00f6de under H1<\/td><\/tr><tr><td>V\u00e4rde av data<\/td><td>St\u00f6rre plattformspotential<\/td><td>Skyddar en befintlig int\u00e4ktsk\u00e4lla<\/td><\/tr><tr><td>Tv\u00e5 dagars kursr\u00f6relse<\/td><td>+177%, tappade sedan cirka en femtedel<\/td><td>+12,6%, beh\u00f6ll i stort uppg\u00e5ngen<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Modernas m\u00f6jlighet bygger p\u00e5 \u201doptioner\u201d \u2013 att tekniken kan ge m\u00e5nga utfall men med os\u00e4kerhet. Bolaget har <a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/moderna-shares-surge-more-90-132957599.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">nio fas 2\u2011 och fas 3\u2011studier<\/a> med intismeran inom melanom, icke\u2011sm\u00e5cellig lungcancer (vanlig typ av lungcancer), bl\u00e5scancer och njurcellscancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Om resultaten h\u00e5ller i flera cancerformer blir potentialen mycket st\u00f6rre.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Men m\u00e5nga m\u00f6jliga utfall g\u00f6r v\u00e4rderingen sv\u00e5rare. Ett bolag med lovande teknik men svaga l\u00f6pande int\u00e4kter har inte samma stabilitet som ett bolag med en etablerad stors\u00e4ljare.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Patentutg\u00e5ngar ritar om l\u00e4kemedelssektorn<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Samarbetet Moderna\u2013Merck speglar <a href=\"https:\/\/finance.yahoo.com\/news\/big-pharma-navigating-300-billion-080000758.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">en bredare trend i l\u00e4kemedelsindustrin<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Runt <a href=\"https:\/\/finance.yahoo.com\/news\/big-pharma-navigating-300-billion-080000758.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">300 miljarder dollar i int\u00e4kter fr\u00e5n originall\u00e4kemedel v\u00e4ntas m\u00f6ta patentpress till 2030<\/a>. Samtidigt har aff\u00e4rer och uppk\u00f6p tagit fart n\u00e4r stora bolag s\u00f6ker ny tillv\u00e4xt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sk\u00e4let \u00e4r enkelt: stora l\u00e4kemedelsbolag vill ha nya int\u00e4kter innan gamla minskar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det \u00e4ndrar maktbalansen mellan biotechbolag och stora l\u00e4kemedelskoncerner.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mindre bolag st\u00e5r ofta f\u00f6r innovation. Stora bolag har kapital, erfarenhet av godk\u00e4nnanden och global f\u00f6rs\u00e4ljningsorganisation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hur v\u00e4rdet delas avg\u00f6rs ofta tidigt, n\u00e4r samarbeten f\u00f6rhandlas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00e4rf\u00f6r betyder vetenskaplig bekr\u00e4ftelse inte alltid att uppfinnaren f\u00e5r st\u00f6rsta delen av v\u00e4rdet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech visade en annan sida av dynamiken. Bolaget, som utvecklar egna personanpassade cancervaccin, f\u00f6ll 4% samma dag. Marknaden s\u00e5g resultatet som st\u00f6d f\u00f6r tekniken, men ocks\u00e5 som tecken p\u00e5 h\u00e5rdare konkurrens.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Riskerna bakom optimismen<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Marknadsreaktionen kan \u00e4nd\u00e5 missa delar av bilden.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">St\u00f6rsta utmaningen \u00e4r tillverkningen. Personanpassade cancerbehandlingar kr\u00e4ver att varje dos g\u00f6rs f\u00f6r en specifik patient. Att skala upp produktionen, s\u00e4kra kvalitet och f\u00e5 logistiken att fungera \u00e4r avg\u00f6rande fr\u00e5gor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Om Moderna l\u00f6ser detta kan plattformen bli en tydlig konkurrensf\u00f6rdel.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Priss\u00e4ttning \u00e4r en annan os\u00e4kerhet. Det finns ingen etablerad modell f\u00f6r hur v\u00e5rdsystem ska ers\u00e4tta personanpassade cancerbehandlingar i stor skala. Starka kliniska resultat garanterar inte f\u00f6rs\u00e4ljningsframg\u00e5ng.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det finns ocks\u00e5 ett l\u00e4ngre argument f\u00f6r Moderna.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Om intismeran lyckas i fler cancerformer kan v\u00e4rdet p\u00e5 sikt bli mycket st\u00f6rre \u00e4n marknaden r\u00e4knar med i dag. Skillnaden mellan Moderna och Merck speglar dagens finanser, inte n\u00f6dv\u00e4ndigtvis slutresultatet.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Det h\u00e4r blir n\u00e4sta fokus<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Forskningen har tagit ett steg fram. Nu handlar diskussionen om genomf\u00f6rande och vem som f\u00e5r int\u00e4kterna.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Flera faktorer avg\u00f6r n\u00e4sta steg:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Resultat fr\u00e5n fler studier, s\u00e4rskilt i icke\u2011sm\u00e5cellig lungcancer och bl\u00e5scancer, som kan visa om plattformen fungerar utanf\u00f6r melanom.<br><\/li>\n\n\n\n<li>Tidsplan hos l\u00e4kemedelsmyndigheter och om bolagen kan g\u00e5 snabbt mot diskussioner om godk\u00e4nnande.<br><\/li>\n\n\n\n<li>Modernas finansiella l\u00e4ge och om bolaget kan ta in kapital p\u00e5 b\u00e4ttre villkor efter omv\u00e4rderingen.<br><\/li>\n\n\n\n<li>Nya samarbeten mellan biotech och big pharma, som kan visa om innovat\u00f6rer f\u00e5r mer f\u00f6rhandlingsstyrka.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Att bevisa forskningen och att f\u00e5 ekonomiskt v\u00e4rde \u00e4r tv\u00e5 olika saker. Mercks uppg\u00e5ng h\u00f6ll b\u00e4ttre eftersom resultaten passar in i en aff\u00e4r som redan finns. Modernas gjorde det inte, eftersom den aff\u00e4ren fortfarande byggs.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">En utl\u00f6sande nyhet, tv\u00e5 olika f\u00f6ruts\u00e4ttningar. Moderna handlas p\u00e5 \u201dh\u00e4ndelserisk\u201d \u2013 kursen r\u00f6r sig kraftigt p\u00e5 studier och myndighetsbesked och \u00e4r svagare d\u00e4remellan. Merck b\u00e4r samma cancertema i ett bolag som redan drar in miljarder, vilket hittills gett mindre sv\u00e4ngningar.<\/p>\n\n\n\n<details class=\"wp-block-details is-layout-flow wp-block-details-is-layout-flow\"><summary>Tryck f\u00f6r Trader&#8217;s Takeaway<\/summary>\n<p class=\"wp-block-paragraph\"><br><strong>Vad \u00e4r samarbetet mellan Moderna och Merck kring cancervaccin?<\/strong> <br>Moderna har utvecklat den personanpassade mRNA\u2011behandlingen, medan Merck bidrar med Keytruda och kommersiell erfarenhet. Samarbetet kombinerar Modernas teknik med Mercks cancerv\u00e5rdskompetens.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Varf\u00f6r steg Modernas aktie efter studieresultatet?<\/strong> <br>Moderna rusade efter positiva fas 3\u2011resultat f\u00f6r sin personanpassade mRNA\u2011cancerbehandling, vilket h\u00f6jde f\u00f6rv\u00e4ntningarna p\u00e5 bolagets framtida cancerportf\u00f6lj (pipeline).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Varf\u00f6r gynnades Mercks aktie av Modernas genombrott?<\/strong> <br>Mercks uppg\u00e5ng kopplades till att intismeran kan st\u00e4rka Keytruda\u2011aff\u00e4ren och st\u00f6dja framtida int\u00e4ktstillv\u00e4xt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Varf\u00f6r reagerade aktierna olika p\u00e5 samma genombrott?<\/strong> <br>Moderna st\u00e5r f\u00f6r framtida plattformspotential, medan Merck har en tydligare v\u00e4g till int\u00e4kter via en etablerad cancerverksamhet.<\/p>\n<\/details>\n\n\n\n\n<p class=\"wp-block-paragraph\"><b>B\u00f6rja handla nu \u2014 klicka <a href=\"https:\/\/www.vtmarkets.com\/sv-eu\/trade-now\/\">h\u00e4r<\/a> f\u00f6r att skapa ditt riktiga VT Markets-konto.<\/b>\n\n<\/p>","protected":false},"excerpt":{"rendered":"<p>B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.<\/p>\n","protected":false},"author":87,"featured_media":56274,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[51],"tags":[],"class_list":["post-56275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-opinion"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.\" \/>\n\t<meta name=\"robots\" content=\"max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"VT Markets -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets\" \/>\n\t\t<meta property=\"og:description\" content=\"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-21T08:42:05+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-21T08:42:05+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets\" \/>\n\t\t<meta name=\"twitter:description\" content=\"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#blogposting\",\"name\":\"Moderna, Merck och de olika s\\u00e4tt som marknaden v\\u00e4rderar ett genombrott - VT Markets\",\"headline\":\"Moderna, Merck och de olika s\\u00e4tt som marknaden v\\u00e4rderar ett genombrott\",\"author\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/author\\\/josephine\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/wp-content\\\/uploads\\\/sites\\\/10\\\/2026\\\/08\\\/Moderna-Merck-pharma.webp\",\"width\":1250,\"height\":700},\"datePublished\":\"2026-08-21T08:42:05+00:00\",\"dateModified\":\"2026-08-21T08:42:05+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#webpage\"},\"articleSection\":\"Opinion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/category\\\/opinion\\\/#listItem\",\"name\":\"Opinion\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/category\\\/opinion\\\/#listItem\",\"position\":2,\"name\":\"Opinion\",\"item\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/category\\\/opinion\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#listItem\",\"name\":\"Moderna, Merck och de olika s\\u00e4tt som marknaden v\\u00e4rderar ett genombrott\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#listItem\",\"position\":3,\"name\":\"Moderna, Merck och de olika s\\u00e4tt som marknaden v\\u00e4rderar ett genombrott\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/category\\\/opinion\\\/#listItem\",\"name\":\"Opinion\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/#organization\",\"name\":\"VT Markets\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/author\\\/josephine\\\/#author\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/author\\\/josephine\\\/\",\"name\":\"josephine\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7809ddd0668c6cd297bde70914f1903a959aa8d1a194930855d6c5b37e53a6f0?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"josephine\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#webpage\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/\",\"name\":\"Moderna, Merck och de olika s\\u00e4tt som marknaden v\\u00e4rderar ett genombrott - VT Markets\",\"description\":\"B\\u00f6rsen jublade \\u2013 men sv\\u00e4ngde snabbt. Modernas personanpassade mRNA\\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\\u00e4ktsv\\u00e4g.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/author\\\/josephine\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/author\\\/josephine\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/wp-content\\\/uploads\\\/sites\\\/10\\\/2026\\\/08\\\/Moderna-Merck-pharma.webp\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#mainImage\",\"width\":1250,\"height\":700},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#mainImage\"},\"datePublished\":\"2026-08-21T08:42:05+00:00\",\"dateModified\":\"2026-08-21T08:42:05+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/#website\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/\",\"name\":\"VT Markets\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/sv-eu\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets<\/title>\n\n","aioseo_head_json":{"title":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets","description":"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.","canonical_url":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","robots":"max-snippet:-1, max-image-preview:large, max-video-preview:-1","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#blogposting","name":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets","headline":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott","author":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/author\/josephine\/#author"},"publisher":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma.webp","width":1250,"height":700},"datePublished":"2026-08-21T08:42:05+00:00","dateModified":"2026-08-21T08:42:05+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#webpage"},"isPartOf":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#webpage"},"articleSection":"Opinion"},{"@type":"BreadcrumbList","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu#listItem","position":1,"name":"Home","item":"https:\/\/www.vtmarkets.com\/sv-eu","nextItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/category\/opinion\/#listItem","name":"Opinion"}},{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/category\/opinion\/#listItem","position":2,"name":"Opinion","item":"https:\/\/www.vtmarkets.com\/sv-eu\/category\/opinion\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#listItem","name":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#listItem","position":3,"name":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott","previousItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/category\/opinion\/#listItem","name":"Opinion"}}]},{"@type":"Organization","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/#organization","name":"VT Markets","url":"https:\/\/www.vtmarkets.com\/sv-eu\/"},{"@type":"Person","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/author\/josephine\/#author","url":"https:\/\/www.vtmarkets.com\/sv-eu\/author\/josephine\/","name":"josephine","image":{"@type":"ImageObject","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/7809ddd0668c6cd297bde70914f1903a959aa8d1a194930855d6c5b37e53a6f0?s=96&d=mm&r=g","width":96,"height":96,"caption":"josephine"}},{"@type":"WebPage","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#webpage","url":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","name":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets","description":"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/#website"},"breadcrumb":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#breadcrumblist"},"author":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/author\/josephine\/#author"},"creator":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/author\/josephine\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-content\/uploads\/sites\/10\/2026\/08\/Moderna-Merck-pharma.webp","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#mainImage","width":1250,"height":700},"primaryImageOfPage":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#mainImage"},"datePublished":"2026-08-21T08:42:05+00:00","dateModified":"2026-08-21T08:42:05+00:00"},{"@type":"WebSite","@id":"https:\/\/www.vtmarkets.com\/sv-eu\/#website","url":"https:\/\/www.vtmarkets.com\/sv-eu\/","name":"VT Markets","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.vtmarkets.com\/sv-eu\/#organization"}}]},"og:locale":"en_US","og:site_name":"VT Markets -","og:type":"article","og:title":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets","og:description":"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g.","og:url":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","article:published_time":"2026-08-21T08:42:05+00:00","article:modified_time":"2026-08-21T08:42:05+00:00","twitter:card":"summary_large_image","twitter:title":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott - VT Markets","twitter:description":"B\u00f6rsen jublade \u2013 men sv\u00e4ngde snabbt. Modernas personanpassade mRNA\u2011cancerbehandling med Keytruda klarade fas 3 och aktien rusade 177% innan vinsthemtagningar slog till. Merck steg stabilare: tydligare int\u00e4ktsv\u00e4g."},"aioseo_meta_data":{"post_id":"56275","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"seo_analyzer_scan_date":"2026-08-21 08:44:09","breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":null,"created":"2026-08-21 08:42:06","updated":"2026-08-21 08:44:10","focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.vtmarkets.com\/sv-eu\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.vtmarkets.com\/sv-eu\/category\/opinion\/\" title=\"Opinion\">Opinion<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\tModerna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.vtmarkets.com\/sv-eu"},{"label":"Opinion","link":"https:\/\/www.vtmarkets.com\/sv-eu\/category\/opinion\/"},{"label":"Moderna, Merck och de olika s\u00e4tt som marknaden v\u00e4rderar ett genombrott","link":"https:\/\/www.vtmarkets.com\/sv-eu\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/"}],"_links":{"self":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/posts\/56275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/users\/87"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/comments?post=56275"}],"version-history":[{"count":0,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/posts\/56275\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/media\/56274"}],"wp:attachment":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/media?parent=56275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/categories?post=56275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/tags?post=56275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}